| UTHEALTH HOME ABOUT SBMI A-Z WEBMAIL INSIDE THE UNIVERSITY |
|
|||||||
|
Kinase Fusion Gene:DYNLT1_MAP2K4 |
Kinase Fusion Protein Summary |
 Kinase Fusion gene summary |
| Kinase Fusion partner gene information | Kinase Fusion gene name: DYNLT1_MAP2K4 | KinaseFusionDB ID: KFG1770 | FusionGDB2.0 ID: KFG1770 | Hgene | Tgene | Gene symbol | DYNLT1 | MAP2K4 | Gene ID | 6993 | 6416 | |
| Gene name | dynein light chain Tctex-type 1 | mitogen-activated protein kinase kinase 4 | ||||||||||
| Synonyms | CW-1|TCTEL1|TCTEX1|tctex-1 | JNKK|JNKK1|MAPKK4|MEK4|MKK4|PRKMK4|SAPKK-1|SAPKK1|SEK1|SERK1|SKK1 | ||||||||||
| Cytomap | 6q25.3 | 17p12 | ||||||||||
| Type of gene | protein-coding | protein-coding | ||||||||||
| Description | dynein light chain Tctex-type 1T-complex testis-specific protein 1 homologt-complex-associated-testis-expressed 1-like 1 | dual specificity mitogen-activated protein kinase kinase 4JNK-activated kinase 1JNK-activating kinase 1MAP kinase kinase 4MAPK/ERK kinase 4MAPKK 4MEK 4SAPK/ERK kinase 1c-Jun N-terminal kinase kinase 1c-Jun NH2-terminal kinase kinase 1stress-acti | ||||||||||
| Modification date | 20240305 | 20240403 | ||||||||||
| UniProtAcc | P63172 | P45985 | ||||||||||
| Ensembl transtripts involved in fusion gene | ENST ids | ENST00000367085, ENST00000367089, ENST00000367088, | ENST00000353533, ENST00000415385, ENST00000581941, | |||||||||
| Context (manual curation of fusion genes in KinaseFusionDB) | PubMed: DYNLT1 [Title/Abstract] AND MAP2K4 [Title/Abstract] AND fusion [Title/Abstract] | |||||||||||
| Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) | DYNLT1(159058888)-MAP2K4(12018920), # samples:1 DYNLT1(159065714)-MAP2K4(12018848), # samples:1 | |||||||||||
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Kinase Fusion gene breakpoints across DYNLT1 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Kinase Fusion gene breakpoints across MAP2K4 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Top |
Kinase Fusion Gene Sample Information |
| Kinase Fusion gene information. |
| Kinase Fusion gene information from four resources (ChiTars 5.0, ChimerDB 4.0, COSMIC, and CCLE) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Sample | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp |
| ChiTaRS5.0 | FN110717 | DYNLT1 | chr6 | 159065714 | MAP2K4 | chr17 | 12018848 |
| ChimerDB4 | TCGA-S9-A6U1-01A | DYNLT1 | chr6 | 159058888 | MAP2K4 | chr17 | 12018920 |
Top |
Kinase Fusion ORF Analysis |
| Kinase Fusion information from ORFfinder translation from full-length transcript sequence from KinaseFusionDB. |
| Henst | Tenst | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp | Seq length (transcript) | Seq length (amino acids) |
Top |
Kinase Fusion Amino Acid Sequences |
| For individual full-length fusion transcript sequence from KinaseFusionDB, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
| >Henst_Tenst_Hgene_Hchr_Hbp_Tgene_Tchr_Tbp_length(fusion AA)_AAseq |
Multiple Sequence Alignment of All Fusion Protein Isoforms |
Top |
Kinase Fusion Protein Functional Features |
| Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/:159058888/:12018920) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| DYNLT1 | MAP2K4 |
| FUNCTION: Acts as one of several non-catalytic accessory components of the cytoplasmic dynein 1 complex that are thought to be involved in linking dynein to cargos and to adapter proteins that regulate dynein function. Cytoplasmic dynein 1 acts as a motor for the intracellular retrograde motility of vesicles and organelles along microtubules. Binds to transport cargos and is involved in apical cargo transport such as rhodopsin-bearing vesicles in polarized epithelia. May also be a accessory component of axonemal dynein.; FUNCTION: Plays a role in neuronal morphogenesis; the function is independent of cytoplasmic dynein and seems to be coupled to regulation of the actin cytoskeleton by enhancing Rac1 activity. The function in neurogenesis may be regulated by association with a G-protein beta-gamma dimer. May function as a receptor-independent activator of heterotrimeric G-protein signaling; the activation appears to be independent of a nucleotide exchange. Plays a role in regulating neurogenesis; inhibits the genesis of neurons from precursor cells during cortical development presumably by antagonizing ARHGEF2. Involved in the regulation of mitotic spindle orientation (By similarity). Unrelated to the role in retrograde microtubule-associated movement may play a role in the dimerization of cytoplasmic proteins/domains such as for ACVR2B. Binds to the cytoplasmic domain of ACVR2B and, in vitro, inhibits ACVR2B signaling (PubMed:27502274). {ECO:0000250, ECO:0000269|PubMed:27502274}.; FUNCTION: (Microbial infection) Is involved in intracellular targeting of D-type retrovirus gag polyproteins to the cytoplasmic assembly site. {ECO:0000269|PubMed:18647839}. | FUNCTION: Dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. Essential component of the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling pathway. With MAP2K7/MKK7, is the one of the only known kinase to directly activate the stress-activated protein kinase/c-Jun N-terminal kinases MAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3. MAP2K4/MKK4 and MAP2K7/MKK7 both activate the JNKs by phosphorylation, but they differ in their preference for the phosphorylation site in the Thr-Pro-Tyr motif. MAP2K4 shows preference for phosphorylation of the Tyr residue and MAP2K7/MKK7 for the Thr residue. The phosphorylation of the Thr residue by MAP2K7/MKK7 seems to be the prerequisite for JNK activation at least in response to pro-inflammatory cytokines, while other stimuli activate both MAP2K4/MKK4 and MAP2K7/MKK7 which synergistically phosphorylate JNKs. MAP2K4 is required for maintaining peripheral lymphoid homeostasis. The MKK/JNK signaling pathway is also involved in mitochondrial death signaling pathway, including the release cytochrome c, leading to apoptosis. Whereas MAP2K7/MKK7 exclusively activates JNKs, MAP2K4/MKK4 additionally activates the p38 MAPKs MAPK11, MAPK12, MAPK13 and MAPK14. {ECO:0000269|PubMed:7716521}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - Retained domain in the 5'-partner of fusion protein (protein functional feature from UniProt). |
| Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
| - Retained domain in the 3'-partner of fusion protein (protein functional feature from UniProt). |
| Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
Top |
Kinase-Substrate Information of DYNLT1_MAP2K4 |
| Phosphorylation target of the kinase (phosphosite, 03-17-2024) |
| Kinase | Kinase UniProt Acc | Kinase species | Substrate | Substrate UniProt Acc | Substrate phosphorylated residues | Substrate phosphorylated sites (+/-7AA) | Domain |
| MAP2K4 | P45985 | human | MAPK8 | P45983-2 | Y185 | TSFMMtPyVVTRYYR | Pkinase |
| MAP2K4 | P45985 | human | MAPK9 | P45984 | Y185 | tNFMMtPyVVtRYYR | Pkinase |
| MAP2K4 | P45985 | human | MAPK8 | P45983 | Y185 | tsFMMtPyVVtRYYR | Pkinase |
| MAP2K4 | P45985 | human | RXRA | P19793 | Y249 | VEPKTETyVEANMGL | |
| MAP2K4 | P45985 | human | MAPK10 | P53779 | Y223 | tsFMMtPyVVtRYYR | Pkinase |
| MAP2K4 | P45985 | human | MAP2K4 | P45985 | S257 | ISGQLVDsIAKtRDA | Pkinase |
| MAP2K4 | P45985 | human | MAPK8 | P45983-3 | T228 | GGVLFPGtDHIDQWN | Pkinase |
| MAP2K4 | P45985 | human | MAPK8 | P45983-3 | S377 | GVIRGQPsPLAQVQQ | |
| MAP2K4 | P45985 | human | MAPK10 | P53779-2 | Y223 | TSFMMtPyVVTRYYR | Pkinase |
| MAP2K4 | P45985 | human | MAPK8 | P45983 | T183 | AGtsFMMtPyVVtRY | Pkinase |
| MAP2K4 | P45985 | human | MAPK8 | P45983-3 | T183 | AGTSFMMtPyVVTRY | Pkinase |
| MAP2K4 | P45985 | human | MAPK14 | Q16539 | T180 | RHtDDEMtGyVAtRW | Pkinase |
| MAP2K4 | P45985 | human | MAPK8 | P45983-3 | S284 | DVLFPADsEHNKLKA | Pkinase |
| MAP2K4 | P45985 | human | MAPK8 | P45983-3 | Y185 | TSFMMtPyVVTRYYR | Pkinase |
| MAP2K4 | P45985 | human | MAP2K4 | P45985 | T261 | LVDsIAKtRDAGCRP | Pkinase |
| MAP2K4 | P45985 | human | MAPK14 | Q16539 | Y182 | tDDEMtGyVAtRWYR | Pkinase |
| Biological Network Integration of This Kinase and Substrates (GeneMANIA website) |
| Enriched GO biological processes of the phosphorylation target genes of the kinase |
| Kinase | GOID | GO term | P.adjust |
| MAP2K4 | ID | Description | 0.00e+00 |
| MAP2K4 | GO:0038095 | Fc-epsilon receptor signaling pathway | 7.81e-09 |
| MAP2K4 | GO:0090398 | cellular senescence | 7.81e-09 |
| MAP2K4 | GO:0038093 | Fc receptor signaling pathway | 1.47e-07 |
| MAP2K4 | GO:0051403 | stress-activated MAPK cascade | 1.55e-07 |
| MAP2K4 | GO:0031098 | stress-activated protein kinase signaling cascade | 1.55e-07 |
| MAP2K4 | GO:0007254 | JNK cascade | 5.64e-06 |
| MAP2K4 | GO:0002768 | immune response-regulating cell surface receptor signaling pathway | 9.85e-05 |
| MAP2K4 | GO:0042752 | regulation of circadian rhythm | 2.26e-04 |
| MAP2K4 | GO:0002764 | immune response-regulating signaling pathway | 3.32e-04 |
| MAP2K4 | GO:0034614 | cellular response to reactive oxygen species | 4.46e-04 |
| MAP2K4 | GO:0007623 | circadian rhythm | 8.76e-04 |
| MAP2K4 | GO:0000302 | response to reactive oxygen species | 8.76e-04 |
| MAP2K4 | GO:0009612 | response to mechanical stimulus | 9.06e-04 |
| MAP2K4 | GO:0034599 | cellular response to oxidative stress | 1.44e-03 |
| MAP2K4 | GO:0071276 | cellular response to cadmium ion | 1.59e-03 |
| MAP2K4 | GO:0031281 | positive regulation of cyclase activity | 1.65e-03 |
| MAP2K4 | GO:0018105 | peptidyl-serine phosphorylation | 1.75e-03 |
| MAP2K4 | GO:0048511 | rhythmic process | 1.75e-03 |
| MAP2K4 | GO:0018209 | peptidyl-serine modification | 1.85e-03 |
| MAP2K4 | GO:0062197 | cellular response to chemical stress | 1.85e-03 |
| MAP2K4 | GO:0009416 | response to light stimulus | 1.85e-03 |
| MAP2K4 | GO:0071214 | cellular response to abiotic stimulus | 1.96e-03 |
| MAP2K4 | GO:0104004 | cellular response to environmental stimulus | 1.96e-03 |
| MAP2K4 | GO:0071496 | cellular response to external stimulus | 2.04e-03 |
| MAP2K4 | GO:0031279 | regulation of cyclase activity | 2.04e-03 |
| MAP2K4 | GO:0046686 | response to cadmium ion | 2.34e-03 |
| MAP2K4 | GO:0006979 | response to oxidative stress | 2.84e-03 |
| MAP2K4 | GO:0071260 | cellular response to mechanical stimulus | 3.24e-03 |
| MAP2K4 | GO:0009314 | response to radiation | 3.24e-03 |
| MAP2K4 | GO:0002534 | cytokine production involved in inflammatory response | 3.71e-03 |
| MAP2K4 | GO:1900015 | regulation of cytokine production involved in inflammatory response | 3.71e-03 |
| MAP2K4 | GO:0055017 | cardiac muscle tissue growth | 4.34e-03 |
| MAP2K4 | GO:0031667 | response to nutrient levels | 4.37e-03 |
| MAP2K4 | GO:0060419 | heart growth | 4.85e-03 |
| MAP2K4 | GO:0002532 | production of molecular mediator involved in inflammatory response | 5.62e-03 |
| MAP2K4 | GO:0030278 | regulation of ossification | 7.12e-03 |
| MAP2K4 | GO:0009411 | response to UV | 1.09e-02 |
| MAP2K4 | GO:0090316 | positive regulation of intracellular protein transport | 1.15e-02 |
| MAP2K4 | GO:0035265 | organ growth | 1.40e-02 |
| MAP2K4 | GO:0031334 | positive regulation of protein-containing complex assembly | 1.67e-02 |
| MAP2K4 | GO:0071248 | cellular response to metal ion | 1.67e-02 |
| MAP2K4 | GO:0032388 | positive regulation of intracellular transport | 1.67e-02 |
| MAP2K4 | GO:0033157 | regulation of intracellular protein transport | 2.01e-02 |
| MAP2K4 | GO:0071222 | cellular response to lipopolysaccharide | 2.01e-02 |
| MAP2K4 | GO:0071241 | cellular response to inorganic substance | 2.02e-02 |
| MAP2K4 | GO:0071219 | cellular response to molecule of bacterial origin | 2.15e-02 |
| MAP2K4 | GO:0048738 | cardiac muscle tissue development | 2.24e-02 |
| MAP2K4 | GO:0031669 | cellular response to nutrient levels | 2.26e-02 |
| MAP2K4 | GO:0014706 | striated muscle tissue development | 2.42e-02 |
Top |
Related Drugs to DYNLT1_MAP2K4 |
| Drugs used for this fusion-positive patient. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Drug | Source | PMID |
| Distribution of the number of studies mentioning DYNLT1-MAP2K4 and kinase inhibitors the PubMed Abstract (04-01-2024) |
| Fusion gene - drug pair 1 | Fusion gene - drug pair 2 | PMID | Publication date | DOI | Study title |
Top |
Related Diseases to DYNLT1_MAP2K4 |
| Diseases that have this fusion gene. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Disease | Source | PMID |
| Related diseases from the literature mentioned this fusion gene and drug. (PubMed, 04-01-2024) |
| MeSH ID | MeSH term |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Top |
Clinical Trials of the Found Drugs/Small Molecules |
| Statistics of the Clinical Trials of the Found Kinase Inibitors from clinicaltrials.gov (06-17-2024) |
| Clinical Trials from clinicaltrials.gov (06-17-2024) |
| Fusion Gene | Kinase Inhibitor | NCT ID | Study Status | Phases | Disease | # Enrolment | Date |
Copyright 2024-Present -The University of Texas Health Science Center at Houston
Web File Viewing | Emergency Information |Campus Carry|Site Policies |